INSILICO (03696) intends to repurchase shares on the open market.

date
08:28 30/10/2026
avatar
GMT Eight
Insilico Medicine (03696) announced that the Company has resolved to repurchase its shares on the open market of The Stock Exchange of Hong Kong Limited (the Stock Exchange) from time to time, pursuant to the general mandate (the Repurchase Mandate) granted to the directors at the annual general meeting held on June 2, 2026 and approved by the Company's shareholders, for an aggregate amount of up to HK$500 million (the Share Repurchase).
INSILICO (03696) announced that the Company has decided to repurchase its shares on the open market of The Stock Exchange of Hong Kong Limited (the Stock Exchange) from time to time, pursuant to the general mandate (the Share Repurchase Mandate) granted to the directors at the annual general meeting held on June 2, 2026 and approved by the Company's shareholders, for an aggregate amount of up to HK$500 million (the Share Repurchase). The Board believes that the current trading price of the shares undervalues the Company's intrinsic value and development prospects, and that the Share Repurchase will enhance shareholder value. The Board believes that the Share Repurchase reflects the Company's confidence in its business prospects and development, and will benefit the Company and create value for its shareholders in the long term. The Board believes that the Company has sufficient financial resources to carry out the Share Repurchase while maintaining a sound financial position, without adversely affecting its operations.